- |||||||||| letrozole / generics
Review, Journal: Letrozole pre-treatment prior to medical termination of pregnancy: a systematic review. (Pubmed Central) - Jun 5, 2019 Recruiting --> Active, not recruiting This systematic review demonstrated that a combination of letrozole and misoprostol increased the rate of complete abortion compared to misoprostol alone in some studies, but not in others; additional well designed RCT's are needed.
- |||||||||| letrozole / Generic mfg.
Trial completion, Trial completion date: SOLE: Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer (clinicaltrials.gov) - Jun 4, 2019 P3, N=4884, Completed, The Recurrence Score test is validated to predict clinical response to neoadjuvant letrozole in postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer. Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> May 2019
- |||||||||| letrozole / generics
Review, Journal: Neuroestradiol in regulation of GnRH release. (Pubmed Central) - Jun 4, 2019 Results indicate that letrozole treatment greatly attenuated the EB-induced GnRH and LH surges. Collectively, neuroestradiol released from the hypothalamus appears to be necessary for the positive feedback effect of Eon the GnRH/LH surge.
- |||||||||| Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Enrollment open, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - May 31, 2019 P1/2, N=25, Recruiting, Collectively, neuroestradiol released from the hypothalamus appears to be necessary for the positive feedback effect of Eon the GnRH/LH surge. Active, not recruiting --> Recruiting
- |||||||||| letrozole / generics, lithium / generics
Preclinical, Journal: Exposure of Hyperandrogen During Pregnancy Causes Depression- and Anxiety-Like Behaviors, and Reduced Hippocampal Neurogenesis in Rat Offspring. (Pubmed Central) - May 30, 2019 The lithium chloride (LICl) was used as an intervention agent since a previous study has shown that lithium chloride could promote neurogenesis in the hippocampus...Furthermore, the Wnt/β-catenin signaling pathway related to normal development of hippocampus was examined but there was no significant changes in Wnt signaling pathway members. Our study provides evidence that exposure of androgen during pregnancy leads to alterations in depressive, anxious and stereotypical behaviors and these phenotypes are possibly associated with changes in neurogenesis in the dentate gyrus.
- |||||||||| everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - May 30, 2019 P2, N=48, Active, not recruiting, Our study provides evidence that exposure of androgen during pregnancy leads to alterations in depressive, anxious and stereotypical behaviors and these phenotypes are possibly associated with changes in neurogenesis in the dentate gyrus. Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
- |||||||||| Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, pictilisib (GDC-0941) / Roche
P1 data, Journal, Combination therapy: A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. (Pubmed Central) - May 29, 2019 P1 Combining pictilisib with paclitaxel, with and without bevacizumab or trastuzumab, or letrozole, had a manageable safety profile in patients with locally recurrent or metastatic breast cancer. The combination had antitumor activity, and the additive effect of pictilisib supported further investigation in a randomized study.
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, Metastases: To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer (clinicaltrials.gov) - May 29, 2019 P1, N=79, Completed, Our study is helpful to inform the multilateral drug price negotiations in China that may be upcoming for RIB. Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: TRial on the Endocrine Activity of Neoadjuvant Degarelix (clinicaltrials.gov) - May 29, 2019 P2, N=51, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 Active, not recruiting --> Completed
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment closed, Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases: BioItaLEE: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (clinicaltrials.gov) - May 28, 2019 P3, N=287, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Nov 2022 | Trial primary completion date: Oct 2021 --> Dec 2020
- |||||||||| Kisqali (ribociclib) / Novartis
Journal: Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer. (Pubmed Central) - May 24, 2019 There are no available published data regarding the combination of ribociclib and palliative RT. We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC.
- |||||||||| NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) - May 24, 2019 P=N/A, N=90, Recruiting, We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC. Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2018 --> Mar 2021
- |||||||||| Herceptin (trastuzumab) / Roche
Review, Journal: Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. (Pubmed Central) - May 15, 2019 Avitinib, olmutinib, and pelitinib are additional type VI inhibitors in clinical trials for non-small cell lung cancer that target EGFR. Secondary resistance to both targeted and cytotoxic drugs is the norm, and devising and implementing strategies for minimizing or overcoming resistance is an important goal in cancer therapeutics.
- |||||||||| Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - May 15, 2019 P2, N=22, Recruiting, Secondary resistance to both targeted and cytotoxic drugs is the norm, and devising and implementing strategies for minimizing or overcoming resistance is an important goal in cancer therapeutics. Trial completion date: Feb 2020 --> Sep 2020 | Trial primary completion date: Feb 2020 --> Sep 2020
- |||||||||| letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Trial completion date, Metastases: PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) - May 14, 2019 P1, N=42, Active, not recruiting, Trial completion date: Feb 2020 --> Sep 2020 | Trial primary completion date: Feb 2020 --> Sep 2020 Recruiting --> Active, not recruiting | Trial completion date: Jul 2019 --> Jul 2020
- |||||||||| Ibrance (palbociclib) / Pfizer
Clinical, Journal: Pharmacological profile and clinical findings of palbociclib (IBRANCE capsule 25 mg/125 mg) (Pubmed Central) - May 7, 2019 In the PALOMA-3 study, the combination of palbociclib and fulvestrant was associated with significant improvements in PFS compared with fulvestrant plus placebo in patients with metastatic breast cancer. The rate of dose reduction or interruption of dosing by adverse events is higher in palbociclib group compared with placebo group in both studies while the rate of discontinuation of treatment was comparable.
- |||||||||| Journal: Comprehensive Genomic Profiling Aids in Treatment of a Metastatic Endometrial Cancer. (Pubmed Central) - May 2, 2019
Additionally, clinical benefit from an mTOR inhibitor may reflect a response to targeting the alteration in PIK3CA or TSC2 . More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion.
- |||||||||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial primary completion date, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - May 2, 2019 P2, N=55, Recruiting, More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion. Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2019 --> Aug 2019
- |||||||||| letrozole / generics
Clinical, Journal, Monotherapy: Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height. (Pubmed Central) - Apr 27, 2019 The Lz-treated boys had similar adult heights with the subjects who received Pl for 2 years, which indicates that the treatment is not beneficial when given to pre- or early-pubertal boys. Previously observed vertebral deformities ameliorated during follow-up, which supports the skeletal safety of Lz therapy in children and adolescents.
|